Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL23726528

N.N.c1ccc(C(OC(c2ccccc2)(c2ccccc2)c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.46
MAPK1 P28482 1/20 0.43
KCNN4 O15554 4/20 0.43
TSHR P16473 3/20 0.43
ALDH1A1 P00352 3/20 0.43
ALOX15 P16050 1/20 0.40
CYP1A2 P05177 2/20 0.35
TAAR1 Q96RJ0 1/20 0.35
PTPN1 P18031 1/20 0.33
LTA4H P09960 1/20 0.33
ESR1 P03372 1/20 0.33
CYP3A4 P08684 1/20 0.33
ESR2 Q92731 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8973 0.97 KIF11 (0.48) KIF11MAPK1KCNN4TSHRALDH1A1
Bromide SCHEMBL28557682 0.94 KIF11 (0.46) KIF11MAPK1KCNN4TSHRALDH1A1
Hydrochloric Acid SCHEMBL28556207 0.94 KIF11 (0.46) KIF11MAPK1KCNN4TSHRALDH1A1
Fluoride SCHEMBL27919232 0.94 KIF11 (0.46) KIF11MAPK1KCNN4TSHRALDH1A1
SCHEMBL28297324 0.94 KIF11 (0.46) KIF11MAPK1KCNN4TSHRALDH1A1
Formaldehyde SCHEMBL27751011 0.88 KIF11 (0.43) KIF11MAPK1KCNN4TSHRALDH1A1
SCHEMBL396515 0.86 KIF11 (0.41) KIF11MAPK1KCNN4TSHRALDH1A1
Ethylene Glycol SCHEMBL11275979 0.84 KIF11 (0.45) KIF11MAPK1KCNN4TSHRALDH1A1
SCHEMBL1764124 0.82 KIF11 (0.43) KIF11MAPK1KCNN4TSHRALDH1A1
SCHEMBL28958532 0.82 ESR1 (0.58) KIF11TSHRALDH1A1ALOX15CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230040236-A1 Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications PALATIN TECHNOLOGIES, INC. (US) 2023-02-09 US disclosed
CN-115515617-A Diamine-linked receptor-specific cyclic peptides 帕拉丁科技公司 2022-12-23 CN disclosed
EP-4100040-A1 DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES Palatin Technologies, Inc. (US) 2022-12-14 EP disclosed
WO-2021158463-A1 DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES PALATIN TECHNOLOGIES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040236-A1 Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications MC1R, MC3R, MC5R KIF11 3516/4885MAPK1 1349/4885KCNN4 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.